Juneko E. Grilley‐Olson

3.7k total citations
94 papers, 1.5k citations indexed

About

Juneko E. Grilley‐Olson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Juneko E. Grilley‐Olson has authored 94 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 28 papers in Otorhinolaryngology. Recurrent topics in Juneko E. Grilley‐Olson's work include Head and Neck Cancer Studies (27 papers), Lung Cancer Treatments and Mutations (21 papers) and Cancer Genomics and Diagnostics (18 papers). Juneko E. Grilley‐Olson is often cited by papers focused on Head and Neck Cancer Studies (27 papers), Lung Cancer Treatments and Mutations (21 papers) and Cancer Genomics and Diagnostics (18 papers). Juneko E. Grilley‐Olson collaborates with scholars based in United States, Canada and France. Juneko E. Grilley‐Olson's co-authors include Jared Weiss, D. Neil Hayes, Bhishamjit S. Chera, Robert J. Amdur, Mark C. Weissler, William M. Mendenhall, Adam M. Zanation, Trevor Hackman, Nathan Sheets and Joel E. Tepper and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Juneko E. Grilley‐Olson

92 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Juneko E. Grilley‐Olson United States	23	716	539	414	414	345	94	1.5k
Lisle M. Nabell United States	23	726 1.0×	487 0.9×	603 1.5×	413 1.0×	307 0.9×	57	1.9k
J. Biau France	20	440 0.6×	471 0.9×	340 0.8×	329 0.8×	260 0.8×	113	1.3k
Christopher Milross Australia	27	971 1.4×	520 1.0×	480 1.2×	726 1.8×	560 1.6×	55	2.5k
Assuntina G. Sacco United States	23	787 1.1×	588 1.1×	329 0.8×	550 1.3×	525 1.5×	60	1.8k
Vinita Takiar United States	21	370 0.5×	468 0.9×	487 1.2×	373 0.9×	362 1.0×	100	1.6k
Petr Szturz Czechia	18	494 0.7×	350 0.6×	269 0.6×	427 1.0×	307 0.9×	85	1.2k
Saad A. Khan United States	20	840 1.2×	412 0.8×	220 0.5×	194 0.5×	249 0.7×	89	1.4k
David M. Neskey United States	27	801 1.1×	397 0.7×	490 1.2×	618 1.5×	651 1.9×	67	2.0k
Jared Weiss United States	24	1.1k 1.5×	1.1k 2.0×	430 1.0×	730 1.8×	630 1.8×	104	2.2k
Meredith A. Goldwasser United States	17	1.4k 2.0×	969 1.8×	875 2.1×	670 1.6×	558 1.6×	29	2.7k

Countries citing papers authored by Juneko E. Grilley‐Olson

Since Specialization

Citations

This map shows the geographic impact of Juneko E. Grilley‐Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juneko E. Grilley‐Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juneko E. Grilley‐Olson more than expected).

Fields of papers citing papers by Juneko E. Grilley‐Olson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juneko E. Grilley‐Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juneko E. Grilley‐Olson. The network helps show where Juneko E. Grilley‐Olson may publish in the future.

Co-authorship network of co-authors of Juneko E. Grilley‐Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Juneko E. Grilley‐Olson. A scholar is included among the top collaborators of Juneko E. Grilley‐Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juneko E. Grilley‐Olson. Juneko E. Grilley‐Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferris, Robert L., Rom S. Leidner, Christine H. Chung, et al.. (2025). Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 13(8). e011633–e011633. 1 indexed citations

McDuff, Susan G. R., Derrick Renner, Rahul K. Kollipara, et al.. (2025). Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study. Annals of Surgical Oncology. 32(11). 8299–8308. 1 indexed citations

Grilley‐Olson, Juneko E., William R. Jeck, Charles Kim, et al.. (2025). Management of Desmoid Tumors. Current Oncology Reports. 27(11). 1209–1220.

Rosenberger, Laura H., et al.. (2025). ASO Author Reflections: Circulating Tumor DNA as a Potential Emerging Biomarker in Malignant Phyllodes Tumors. Annals of Surgical Oncology. 32(11). 8309–8310. 1 indexed citations

Rosenberger, Laura H., Richard F. Riedel, Emilia J. Diego, et al.. (2024). Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities. The Oncologist. 29(12). 1024–1031. 9 indexed citations

Cho, Byoung Chul, Konstantin Penkov, Igor Bondarenko, et al.. (2023). A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. ESMO Open. 8(4). 101589–101589. 4 indexed citations

Jeck, William R., et al.. (2023). A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma. Current Treatment Options in Oncology. 24(3). 212–228. 4 indexed citations

Hu‐Lieskovan, Siwen, Fadi Braiteh, Juneko E. Grilley‐Olson, et al.. (2021). Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration. Targeted Oncology. 16(6). 773–787. 2 indexed citations

Chawla, Sant P., Sanjay Goel, Warren Chow, et al.. (2020). A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. Clinical Cancer Research. 26(16). 4225–4232. 29 indexed citations

10.

Weiss, Jared, Siddharth Sheth, Allison M. Deal, et al.. (2020). Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication. Clinical Cancer Research. 26(16). 4260–4267. 29 indexed citations

11.

Adkins, Douglas R., Jessica Ley, Prakash Neupane, et al.. (2019). Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. The Lancet Oncology. 20(9). 1295–1305. 86 indexed citations

12.

Chera, Bhisham, Robert J. Amdur, Colette J. Shen, et al.. (2018). Initial Results from a Phase 2 Prospective Trial of De-intensified Chemoradiation therapy for Low-Risk HPV-associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1309–1310. 2 indexed citations

13.

Alberts, Steven R., Carol E. Peña, Isabelle Genvresse, et al.. (2018). Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. British Journal of Cancer. 118(4). 462–470. 34 indexed citations

14.

Pearlstein, Kevin A., Kyle Wang, Robert J. Amdur, et al.. (2018). Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics. 103(3). 646–653. 24 indexed citations

15.

Subbiah, Vivek, Juneko E. Grilley‐Olson, Austin J. Combest, et al.. (2017). Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. 24(1). 43–51. 82 indexed citations

16.

Bahleda, Rastislav, Juneko E. Grilley‐Olson, Ramaswamy Govindan, et al.. (2017). Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer. 116(12). 1505–1512. 22 indexed citations

17.

Falchook, Aaron D., Gregg Tracton, Anna C. Snavely, et al.. (2016). Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: A prospective feasibility study. Advances in Radiation Oncology. 1(2). 115–121. 42 indexed citations

18.

Chera, Bhishamjit S., Robert J. Amdur, Joel E. Tepper, et al.. (2015). A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 93(3). S2–S2. 4 indexed citations

19.

Weiss, Jared, Liza C. Villaruz, Mark A. Socinski, et al.. (2014). A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. Lung Cancer. 86(2). 288–290. 20 indexed citations

20.

Kim, Richard D., Steven R. Alberts, Isabelle Genvresse, et al.. (2014). Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.. Journal of Clinical Oncology. 32(15_suppl). 2610–2610. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact